Investments

ICON Financial Restatement Impacts Clinical Trial Operations
Management & Regulatory ICON Financial Restatement Impacts Clinical Trial Operations

The sudden announcement from ICON plc regarding a massive restatement of financial results for the 2023 and 2024 fiscal years has sent profound shockwaves through the global clinical research community, forcing a critical re-evaluation of how financial integrity influences day-to-day operations at

UK Redesigns AI Regulation to Fuel Healthcare Innovation
Management & Regulatory UK Redesigns AI Regulation to Fuel Healthcare Innovation

The rapid convergence of clinical medicine and computational intelligence has reached a critical juncture where the speed of technological adoption determines the survivability of modern national health systems. In a bold effort to remain competitive, the United Kingdom has initiated a

Northwestern’s Center for Synthetic Biology Marks Ten Years
Management & Regulatory Northwestern’s Center for Synthetic Biology Marks Ten Years

For the past ten years, the Northwestern University Center for Synthetic Biology has fundamentally altered how researchers perceive the inherent capabilities of living systems by treating genetic code as a programmable substrate for engineering solutions. Since its establishment, the center has

Is Localized Manufacturing the Future of Cell Therapy?
Management & Regulatory Is Localized Manufacturing the Future of Cell Therapy?

Oncology and regenerative medicine are no longer defined solely by the discovery of new molecules but by the sophisticated engineering of living systems to combat terminal illness. The Cell Therapy Manufacturing Center, a strategic joint venture between Resilience and the MD Anderson Cancer Center,

How Will a $31 Million Investment Strengthen Biosecurity?
Management & Regulatory How Will a $31 Million Investment Strengthen Biosecurity?

The vulnerability of modern agricultural supply chains becomes increasingly apparent as rapid globalization and changing climate patterns facilitate the swift movement of invasive species and pathogens across traditional geographic boundaries. A single breach in biosecurity protocols can lead to

Eli Lilly Acquires Engage Bio to Boost Genetic Medicine Portfolio
Management & Regulatory Eli Lilly Acquires Engage Bio to Boost Genetic Medicine Portfolio

The pharmaceutical landscape is currently witnessing a massive transformation as Eli Lilly and Company accelerates its dominance by acquiring Engage Bio, a San Carlos-based firm specializing in non-viral genetic medicine. This strategic move, valued at approximately $202 million including

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later